SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2025 and provided a summary of recent pipeline and corporate highlights. “Our team is laser focused on driving SENTI-202 clinical development forward. With important milestones achieved in the third qua ...

Core Insights - Senti Biosciences, Inc. is set to present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025, in New York, NY [1] - The company is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - Management will also engage in one-on-one meetings with qualified investors during the conference [2] Company Overview - Senti Bio is a clinical-stage biotechnology company targeting incurable diseases through innovative cell and gene therapies [3] - The company utilizes a synthetic biology platform to engineer Gene Circuits aimed at precisely targeting and killing cancer cells while sparing healthy cells [3] - Senti Bio's pipeline includes cell therapies designed for challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3] Additional Information - Investors and the public can access more information about Senti Bio through its website and social media platforms [4] - The company emphasizes the importance of its online communications for investor relations and public disclosures [4]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [2] Upcoming Presentation - Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, will present at the MedInvest Biotech & Pharma Conference on September 24, 2025, at 9:55 AM PT [1] - A live webcast of the presentation will be available on the company's website [2] Investor Engagement - Management will be available for one-on-one meetings with qualified members of the investor community registered for the conference [2] - The company encourages investors and the public to review information posted on its website and social media platforms regularly [3]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Presentation - Senti Bio will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:20 PM ET [1] - The presentation will be led by Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio [1] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][4] - The company recently announced the recommended Phase 2 dose selection for its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy, SENTI-202, aimed at treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [3] Company Overview - Senti Bio is leveraging synthetic biology to engineer Gene Circuits that enhance precision and control in new medicines, specifically targeting cancer cells while sparing healthy cells [4] - The company's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in both NK and T cells [4] Recent Developments - The participation in the Virtual Investor segment highlights the company's ongoing efforts to communicate its advancements and strategies to potential investors [2][3] - The focus on SENTI-202 represents a significant step in Senti Bio's clinical development, indicating progress in its research and development initiatives [3]

Core Insights - Senti Bio is presenting its innovative logic-gated CAR-NK cell therapy, which targets leukemic cells while preserving healthy bone marrow [1] - The presentation will take place at the BioScience Forum on July 23, 2025, featuring Dr. Kanya Rajangam as the speaker [2] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][4] - The company aims to create therapies that can precisely kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing control post-administration [4] - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting both liquid and solid tumors, with preclinical evidence supporting their efficacy in NK and T cells [4]

Core Insights - Senti Biosciences, Inc. has appointed Bryan Baum to its Board of Directors, enhancing its leadership team with his extensive entrepreneurial and investment experience [1][3][4] - Bryan Baum is recognized for his successful track record in scaling companies and has invested in notable firms such as SpaceX, OpenAI, and Airbnb, which may provide strategic advantages to Senti Bio [2][3] - The company is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, aiming to address cancer treatments that current drugs cannot [3][5] Company Overview - Senti Bio is a clinical-stage biotechnology company that leverages synthetic biology to engineer Gene Circuits for new medicines, targeting incurable diseases [5] - The company's pipeline includes cell therapies designed to specifically target and kill cancer cells while sparing healthy cells, with preclinical evidence supporting their efficacy in both NK and T cells [5] - Senti Bio is also exploring the potential of Gene Circuits in other disease modalities beyond oncology, indicating a broad scope for future development [5]

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference, highlighting its innovative approach to tumor-specific therapies [1] Company Overview - Senti Bio is dedicated to creating new cell and gene therapies for patients with incurable diseases, utilizing synthetic biology to engineer Gene Circuits for enhanced precision and control [3] - The company's pipeline includes cell therapies designed to target both liquid and solid tumors, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3] Conference Details - The SEED Conference, established in 2014, serves as a premier event for synthetic biologists, facilitating networking and collaboration among over 5,000 professionals in the field [1] - Senti Bio's presentation will focus on "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells," showcasing its advancements in the field [1]

Core Insights - Senti Biosciences, Inc. is participating in a Virtual Fireside Chat hosted by Chardan Capital Markets on June 9, 2025, featuring key executives discussing the company's advancements in biotechnology [1][2]. Company Overview - Senti Biosciences is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3]. - The company aims to create therapies that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for controllability post-administration [3]. - Senti's pipeline includes cell therapies engineered with Gene Circuits targeting both liquid and solid tumors, with preclinical evidence supporting their efficacy in NK and T cells [3]. Additional Information - For further details, Senti Biosciences encourages stakeholders to visit their official website and follow their social media channels for updates and disclosures [4].

Core Insights - Senti Biosciences, Inc. announced positive preliminary clinical results for its lead program, SENTI-202, targeting Relapsed/Refractory AML [1] - The company will present these results at the Citizens JMP Life Sciences Conference on May 8, 2025, in New York [1][2] - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] Company Overview - Senti Bio is a clinical-stage biotechnology company dedicated to creating innovative cell and gene therapies for patients with incurable diseases [3] - The company utilizes a synthetic biology platform to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [3] - Senti Bio's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3]